Clinical Trials Browser

Uterine Cervical Neoplasms × tisotumab vedotin × 90 days × Clear all

NCT03786081 2026-03-13

Safety and Efficacy of Tisotumab Vedotin Monotherapy & in Combination With Other Cancer Agents in Subjects With Cervical Cancer

Phase 1/2 Active not recruiting

Uterine Cervical Neoplasms

NCT06459180 2026-03-13

TroFuse-020

Phase 3 Recruiting

Uterine Cervical Neoplasms

NCT04697628 2026-02-24

innovaTV 301

Phase 3 Completed

502 enrolled 18 charts 1 FDA

Uterine Cervical Neoplasms